Literature DB >> 18852269

Testing of experimental compounds in a relapse model of tuberculosis using granulocyte-macrophage colony-stimulating factor gene-disrupted mice.

Lisa K Woolhiser1, Donald R Hoff, Karen S Marietta, Ian M Orme, Anne J Lenaerts.   

Abstract

This study describes an in vivo model for evaluating the sterilizing activity of compounds against persisting Mycobacterium tuberculosis. The initial treatment with isoniazid and rifampin in granulocyte-macrophage colony-stimulating factor gene-disrupted mice reduced the number of bacteria more than 99% within 3 weeks. A subsequent treatment with individual drugs was performed to assess their activity on the 1% of remaining bacilli and disease relapse.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852269      PMCID: PMC2612139          DOI: 10.1128/AAC.01346-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Bacterial persistence as a phenotypic switch.

Authors:  Nathalie Q Balaban; Jack Merrin; Remy Chait; Lukasz Kowalik; Stanislas Leibler
Journal:  Science       Date:  2004-08-12       Impact factor: 47.728

2.  Reactivation of latent tuberculosis: variations on the Cornell murine model.

Authors:  C A Scanga; V P Mohan; H Joseph; K Yu; J Chan; J L Flynn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors:  B P Kelly; S K Furney; M T Jessen; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

5.  Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.

Authors:  A M Lenaerts; S E Chase; A J Chmielewski; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Bacterial persistence: a model of survival in changing environments.

Authors:  Edo Kussell; Roy Kishony; Nathalie Q Balaban; Stanislas Leibler
Journal:  Genetics       Date:  2005-01-31       Impact factor: 4.562

Review 7.  Tuberculosis. Scientific blueprint for tuberculosis drug development.

Authors: 
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

8.  Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

Authors:  Tetsuyuki Yoshimatsu; Eric Nuermberger; Sandeep Tyagi; Richard Chaisson; William Bishai; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 9.  The search for new sterilizing anti-tuberculosis drugs.

Authors:  Denis A Mitchison
Journal:  Front Biosci       Date:  2004-05-01

10.  Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy.

Authors:  R M MCCUNE; R TOMPSETT
Journal:  J Exp Med       Date:  1956-11-01       Impact factor: 14.307

View more
  3 in total

1.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

2.  Discovery and validation of new antitubercular compounds as potential drug leads and probes.

Authors:  Robert C Goldman; Barbara E Laughon
Journal:  Tuberculosis (Edinb)       Date:  2009-08-28       Impact factor: 3.131

3.  Tuberculosis recurrence in a priority city in the state of São Paulo, Brazil.

Authors:  Amadeu Antonio Vieira; Danila Torres Leite; Solange Adreoni
Journal:  J Bras Pneumol       Date:  2017 Mar-Apr       Impact factor: 2.624

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.